Genital powder use and risk of uterine cancer: A pooled analysis of prospective studies.


Journal

International journal of cancer
ISSN: 1097-0215
Titre abrégé: Int J Cancer
Pays: United States
ID NLM: 0042124

Informations de publication

Date de publication:
01 06 2021
Historique:
revised: 23 11 2020
received: 19 08 2020
accepted: 09 12 2020
pubmed: 13 1 2021
medline: 14 9 2021
entrez: 12 1 2021
Statut: ppublish

Résumé

When powder is applied to the genital area, it has the potential to reach internal reproductive organs and promote carcinogenesis by irritating and inflaming exposed tissues. Although many studies have considered the association between genital powder use and ovarian cancer risk, the relationship between genital powder use and uterine cancer is less well-studied. We pooled data from four large, prospective cohorts (the Nurses' Health Study, the Nurses' Health Study II, the Sister Study and the Women's Health Initiative - Observational Study). We used Cox proportional hazards models to estimate hazard ratios (HRs) and 95% confidence intervals (CIs), adjusting for prespecified confounders. In total, 209 185 women were included, with 37% reporting ever genital powder use. Over a mean 14.5 years of follow-up, 3272 invasive uterine cancers were diagnosed. There was no overall association between ever genital powder use and uterine cancer (HR = 1.01, 95% CI: 0.94-1.09), with little difference observed for frequent (≥1 times/week) vs never use (HR = 1.05, 95% CI: 0.95-1.16; P-for-trend = .46). Long-term use (>20 years; HR = 1.12, 95% CI: 0.96-1.31; P-for-trend = 0.14) was associated with a small, but not statistically significant, increase in risk, compared to never use. There were not clear differences by uterine cancer histologic subtypes or across strata of relevant covariates, including race/ethnicity, follow-up time, menopausal status and body mass index. The results of this large, pooled analysis do not support a relationship between the use of genital powder and uterine cancer, although the positive associations observed for long-term use may merit further consideration.

Identifiants

pubmed: 33433939
doi: 10.1002/ijc.33470
pmc: PMC8106926
mid: NIHMS1692854
doi:

Substances chimiques

Talc 14807-96-6

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, N.I.H., Intramural Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

2692-2701

Subventions

Organisme : NHLBI NIH HHS
ID : HHSN268201600002C
Pays : United States
Organisme : NCI NIH HHS
ID : P01 CA087969
Pays : United States
Organisme : NCI NIH HHS
ID : UM1 CA176726
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA176726
Pays : United States
Organisme : NCI NIH HHS
ID : K22 CA193860
Pays : United States
Organisme : NHLBI NIH HHS
ID : HHSN268201600003C
Pays : United States
Organisme : NCI NIH HHS
ID : UM1 CA186107
Pays : United States
Organisme : NHLBI NIH HHS
ID : HHSN268201600004C
Pays : United States
Organisme : NHLBI NIH HHS
ID : HHSN268201600001C
Pays : United States
Organisme : Intramural NIH HHS
ID : Z01 ES044005
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA067262
Pays : United States
Organisme : NHLBI NIH HHS
ID : HHSN268201600018C
Pays : United States

Informations de copyright

© 2021 UICC. This article has been contributed to by US Government employees and their work is in the public domain in the USA.

Références

J Clin Oncol. 2019 Aug 1;37(22):1895-1908
pubmed: 31116674
Epidemiology. 2018 Jan;29(1):41-49
pubmed: 28863045
Cancer Epidemiol Biomarkers Prev. 2010 May;19(5):1269-75
pubmed: 20406962
Cancer Epidemiol Biomarkers Prev. 2016 Oct;25(10):1411-1417
pubmed: 27197282
Obstet Gynecol. 1995 Feb;85(2):304-13
pubmed: 7824251
Cancer Epidemiol Biomarkers Prev. 2005 Dec;14(12):2840-7
pubmed: 16364998
Cancer Prev Res (Phila). 2013 Aug;6(8):811-21
pubmed: 23761272
Obstet Gynecol. 1998 Nov;92(5):753-6
pubmed: 9794663
Cancer Epidemiol Biomarkers Prev. 2016 Oct;25(10):1369-1370
pubmed: 27697794
Int J Toxicol. 2015 Jul-Aug;34(1 Suppl):66S-129S
pubmed: 26227892
Cancer Causes Control. 2012 Oct;23(10):1673-80
pubmed: 22875750
Ann Oncol. 2015 Aug;26(8):1635-48
pubmed: 25791635
Am J Epidemiol. 2013 Apr 15;177(8):787-99
pubmed: 23492765
Am J Epidemiol. 1997 Mar 1;145(5):459-65
pubmed: 9048520
Control Clin Trials. 1986 Sep;7(3):177-88
pubmed: 3802833
Epidemiology. 2019 Nov;30(6):783-788
pubmed: 31469695
JAMA. 2020 Jan 7;323(1):49-59
pubmed: 31910280
Control Clin Trials. 1998 Feb;19(1):61-109
pubmed: 9492970
Epidemiology. 1999 Jan;10(1):37-48
pubmed: 9888278
J Obstet Gynaecol Br Commonw. 1971 Mar;78(3):266-72
pubmed: 5558843
Cancer Causes Control. 2012 Mar;23(3):513-9
pubmed: 22245995
Epidemiology. 2019 Nov;30(6):845-852
pubmed: 31584892
Biometrics. 1995 Jun;51(2):524-32
pubmed: 7662841
Environ Health Perspect. 2017 Dec 20;125(12):127003
pubmed: 29373861
Cancer Causes Control. 2015 Feb;26(2):287-296
pubmed: 25534916
Epidemiology. 2016 May;27(3):334-46
pubmed: 26689397
Regul Toxicol Pharmacol. 1995 Apr;21(2):254-60
pubmed: 7644715
Am J Public Health. 2016 Sep;106(9):1573-81
pubmed: 27459450
Cancer Epidemiol Biomarkers Prev. 2013 Feb;22(2):275-85
pubmed: 23292084

Auteurs

Katie M O'Brien (KM)

Epidemiology Branch, National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina, USA.

Shelley S Tworoger (SS)

Department of Cancer Epidemiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA.
Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.

Holly R Harris (HR)

Department of Epidemiology, School of Public Health, University of Washington, Seattle, Washington, USA.
Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.

Britton Trabert (B)

Metabolic Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland, USA.

Clarice R Weinberg (CR)

Biostatistics and Computational Biology Branch, National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina, USA.

Renee T Fortner (RT)

Division of Cancer Epidemiology, German Cancer Research Center, Heidelberg, Germany.

Aimee A D'Aloisio (AA)

Social and Scientific Systems, Inc., Durham, North Carolina, USA.

Andrew M Kaunitz (AM)

Department of Obstetrics and Gynecology, University of Florida College of Medicine- Jacksonville, Jacksonville, Florida, USA.

Nicolas Wentzensen (N)

Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland, USA.

Dale P Sandler (DP)

Epidemiology Branch, National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH